Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Maxcyte (MXCT) Long-Term Debt Repayments (2021)

Maxcyte has reported Long-Term Debt Repayments over the past 1 years, most recently at $4.9 million for Q1 2021.

Quarterly Long-Term Debt Repayments changed N/A to $4.9 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2021, changed N/A year-over-year, with the annual reading at $4.9 million for FY2021, 241.83% up from the prior year.
Long-Term Debt Repayments was $4.9 million for Q1 2021 at Maxcyte.
Over five years, Long-Term Debt Repayments peaked at $4.9 million in Q1 2021 and troughed at $4.9 million in Q1 2021.